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In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modifi-
cation and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). When using the 
first medication for diabetic patients, the appropriate treatment should be selected considering the clinical characteristics of the 
patient, efficacy of the drug, side effects, and cost. In general, the use of metformin as the first treatment for oral hypoglycemic 
monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven 
safety, low risk of hypoglycemia, and low weight gain. If metformin is difficult to use as a first-line treatment, other appropriate 
medications should be selected in view of the clinical situation. If the goal of achieving glycemic control is not achieved by mono-
therapy, a combination therapy with different mechanisms of action should be initiated promptly.
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INTRODUCTION
Many studies have shown that intensive control of blood glu-
cose can significantly prevent diabetes-related chronic compli-
cations [1,2]. These results are the theoretical basis for explain-
ing the need for active blood glucose management to improve 
the clinical course of diabetic patients. However, recent studies 
have reported that overly rigorous blood glucose control may 
lead to a negative clinical course in patients [3-5]. Individual-
ized blood glucose control goals that take into account the di-
verse clinical situations of diabetic patients are required [6,7].
Lifestyle modification (LSM) is the first treatment for suc-
cessful diabetes management. The effects of LSM on the clini-
cal course of diabetes have been demonstrated in several stud-
ies [8,9]. However, due to the pathophysiological nature of type 
2 diabetes mellitus (T2DM), where β-cell function is gradually 
diminishing, it is difficult to maintain adequate blood glucose 
control with LSM alone [10]. Therefore, in many patients, 
medication should be administered from the beginning of the 
treatment for proper blood glucose control.
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This article was written to provide the rationale for the up-
date of the position statement of the Korean Diabetes Associa-
tion (KDA), and the contents of oral hypoglycemic agent 
monotherapy were described.
RECOMMENDATIONS
Principles of initial management after diagnosis of type 2 
diabetes mellitus
1.  Active lifestyle modification and appropriate pharmacother-
apy are needed from the initial diagnosis of diabetes [A].
2.  An appropriate selection of pharmacotherapy should be 
made after considering the clinical characteristics of the pa-
tient and drug efficacy, side effects, mechanism of action, 
risk of hypoglycemia, effect on body weight, and patient 
preference and combined comorbidity [E].
Principles of treatment with antihyperglycemic agents
1.  Metformin is the preferred initial oral hypoglycemic agent 
[A].
2.  If metformin is contraindicated or not well tolerated as the 
initial treatment, another class of hypoglycemic agent can be 
used depending on the clinical situation [E].
3.  If monotherapy fails to achieve the glycemic target, combi-
nation therapy with a second agent with a different mecha-
nism of action should be initiated [A].
METHODS 
Selection of topics, organization of the working group, and 
determination of methods
In March 2017, the Clinical Practice Guideline (CPG) update 
was discussed at the Committee of Clinical Practice Guideline 
in the KDA. The committee decided to carry out an amend-
ment in this revision that reflects the new diabetes medica-
tions. For this task, the committee formed a working group for 
revising the relevant content of the CPG. The guidelines were 
revised based on a systematic review of the newly published 
literature, along with the other national and international CPG 
contents. The details of this process are described in detail in 
other documents [11].
Key question selection
The task of the authors of the current article was evaluating the 
monotherapy of oral hypoglycemic agents for the working 
group. We have determined the key questions for revising the 
CPG according to the results of the discussion within the 
group. The first question is whether metformin is appropriate 
as a first-line choice for Korean patients with T2DM. The sec-
ond question is how to choose the other first-line agent if met-
formin is not available. Finally, cardiovascular outcome with 
metformin or other monotherapy was determined to be the 
third key question.
Literature review
For the purpose of revising the guidelines, various domestic 
and international guidelines have been referred to. We referred 
to the KDA guidelines and the Korea National Diabetes Pro-
gram (KNDP) guidelines as domestic guidelines [12,13] and 
referred to the guidelines of the American Diabetes Associa-
tion (ADA), National Institute for Health and Care Excellence 
(NICE), International Diabetes Federation (IDF), Canadian 
Diabetes Association (CDA), and American Association of 
Clinical Endocrinologists and American College of Endocri-
nology (AACE) as foreign guidelines [14-18]. References that 
meet our key questions were adopted. In addition, a systematic 
review was conducted to obtain the latest evidence. A master 
database for systematic review was built by professional librar-
ians and delivered to group members. The evidence levels of 
the articles in the database were evaluated according to indi-
vidual reviews of the group members. Thereafter, a list of arti-
cles was prepared by mutual review and agreement of group 
members. A final list was established by independent commit-
tee members separate from the working group [11].
Drafting, public hearing, and final approval of board of 
directors
The revised recommendations were circulated and evaluated 
by members of the committee other than the working group. 
Based on peer review, a draft CPG update was prepared. In July 
2017, an initial draft was released at a public hearing. A final 
draft of the CPG update was prepared in accordance with the 
opinions gathered at the hearing. In August 2017, the final 
manuscript was approved by the Board of Directors, KDA.
COMMENTS ON RECOMMENDATIONS 
Oral hypoglycemia agent as a monotherapy
For patients with T2DM who have not satisfactorily met thera-
peutic goals with LSM, a first-line oral hypoglycemic mono-
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therapy should be administered. In monotherapy, approxi-
mately 0.5% to 1.5% of glycosylated hemoglobin (HbA1c) re-
duction is observed depending on the medication [19]. Al-
though there are some differences depending on the class, the 
maximal effect of the drug is usually observed 4 to 6 months 
after treatment [20]. In general, the higher the patient’s HbA1c, 
the greater the extent of HbA1c reduction with medication 
[19]. Postprandial glucose control becomes more important 
for further improvement of HbA1c when blood glucose ap-
proaches the generally recommended level (less than 7.3% of 
HbA1c) [21]. Some studies have shown that postprandial glu-
cose is an independent risk factor for cardiovascular disease 
and death regardless of fasting glucose [22,23]. However, the 
evidence for whether postprandial improvement of blood glu-
cose is effective in improving additional cardiovascular disease 
outcomes is not yet clear.
Metformin as an initial treatment regimen
Metformin is recommended as the drug for initial treatment in 
most diabetes-related CPGs worldwide [12-18]. Metformin is 
recommended as the first choice for patients with T2DM be-
cause of its excellent blood glucose-lowering effect, relatively 
low adverse effects, long-term safety, low risk of hypoglycemia, 
and low weight gain. These recommendations are based on a 
cohort study in which metformin monotherapy in overweight 
T2DM patients was associated with more marked blood glu-
cose-lowering effects and less weight gain and hypoglycemia 
compared to sulfonylurea or insulin monotherapy [24]. Poten-
tial cardiovascular disease prevention effect is also included in 
the reason for choosing metformin as the initial treatment 
[24,25]. However, the preventive effect of metformin on car-
diovascular disease has yet to be ascertained.
In several subsequent observational studies and meta-analy-
ses, there was evidence that metformin could be the drug of 
choice for initial treatment of diabetes patients compared to 
sulfonylurea, thiazolidinedione, and dipeptidyl peptidase 4 
(DPP4) inhibitor, from the aspects of HbA1c reduction, side 
effects, weight gain, hypoglycemia, economic feasibility, and 
cardiovascular disease prevention [26-29]. In a prospective, 
multicenter clinical trial conducted in Korea, the effect of met-
formin monotherapy on HbA1c was similar to that of sulfonyl-
urea or thiazolidinedione monotherapy [30]. Based on the 
above evidence, we also recommend metformin as an initial 
first-line medication in this CPG.
Clinical situations such as hepatic failure, chronic kidney 
disease (caution in estimated glomerular filtration rate [eGFR] 
<60 mL/min/1.73 m2, contraindication in eGFR <30 mL/min/ 
1.73 m2), severe infection, dehydration, and heart failure are 
contraindications of metformin use and it should be used with 
caution [14,17]. Recently, a study suggesting that metformin 
use may be associated with vitamin B12 deficiency and anemia 
was published [31]. Vitamin B12 measurements may be con-
sidered for metformin users with peripheral neuropathy or 
anemia.
Monotherapy using other oral hypoglycemic agents
For patients who are contraindicated for metformin or who 
experience difficulties with metformin use, monotherapy of 
other hypoglycemic agents is considered as an initial treat-
ment. Recently, as new drugs have been launched, various oral 
hypoglycemic agents have become available in clinical practice 
(Table 1) [11]. These drugs differ not only in their mechanism 
of action, but also in terms of cardiovascular disease preven-
tion, side effects, contraindications, and price.
The DPP4 inhibitors have been widely used as a substitute 
for patients who have difficulty in using metformin monother-
apy; these inhibitors are used because of their low incidence of 
side effects such as hypoglycemia. Recently, a meta-analysis 
has been reported by Korean researchers that suggests the ef-
fect of DPP4 inhibitors on Asians may be superior to other 
ethnicities [32]. The effects of the DPP4 inhibitors on cardio-
vascular disease have been reported to be neutral according to 
multicenter, prospective, randomized controlled trials per-
formed recently performed trials [33-35]. Although some 
DPP4 inhibitor have been reported to increase the risk of heart 
failure, systematic reviews have shown that the risk is not sig-
nificant, and there is a slight difference in the risk of heart fail-
ure resulting from the use of DPP4 inhibitors [36,37]. 
The use of sodium-glucose cotransporter 2 (SGLT2) inhibi-
tors has recently led to a significant reduction in the risk of car-
diovascular disease and mortality in patients with diabetes in 
multicenter, prospective, randomized controlled trials, and the 
frequency of use of these inhibitors is increasing in clinical set-
tings [38-41]. However, due to possible side effects such as 
urogenital infection, dehydration, and hypotension, caution 
should be paid to its administration to some individuals such 
as the elderly and patients with chronic kidney disease [38,40]. 
A recent multi-center, prospective, randomized controlled 
clinical trial has reported an increased risk of osteoporotic 
fractures and limb amputation associated with the use of this 
Rhee SY, et al.
352 Diabetes Metab J 2017;41:349-356 http://e-dmj.org
medication [41]. Further research on the long-term safety of 
this drug is needed.
A wide variety of previously used drugs such as sulfonylurea, 
meglitinide, thiazolidinedione, and α-glucosidase inhibitor 
can also be used as an effective substitute for metformin after 
securing various evidence on efficacy and safety when using 
this monotherapy [29,42-44]. There is some evidence that thia-
zolidinedione may reduce the cardiovascular disease risk in 
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Start with lower dose 











Contraindication in severe 
hepatic or renal insuffi-
ciency (eGFR <30 mL/
min/1.73 m2), severe  
infection, dehydration, 
heart failure. Major opera-





↑ Insulin secretion 
from β-cells 
Before meal






↑ Insulin secretion 
from β-cells, ↓ post-
prandial hyperglyce-
mia
Before each meal 








↑ Postprandial incretin 
(GLP-1, GIP), ↑ glu-
cose-dependent insu-
lin secretion, ↓ post-
prandial glucagon se-
cretion, ↓ postprandi-
al hyperglycemia, use 
regardless of meal-
time
No No 0.5–1.0 Angioedema, urti-
caria
Acute pancreatitis 
Risk for heart fail-
ure  (saxagliptin, 
alogliptin)
Dose titration in severe  





↑ Insulin sensitivity 
(muscle, adipose  
tissue), ↓ hepatic  
glucose production, 
once daily regardless 
of mealtime
Yes No 0.5–1.4 Edema, anemia, 
bone fracture, 
heart failure





↓ Renal glucose reab-
sorption, ↑ glucosuria
Once daily regardless of 
mealtime




Old age, heart failure,  
hypotension, diuretics use, 




↓ Upper intestinal  




No No 0.5–1.0 GI side effects (flat-
ulence, diarrhea, 
bloating)
Severe hepatic or renal  
insufficiency, chronic  
inflammatory bowel  
disease with malabsorption, 
severe infection
Adapted Ko et al. [11].
HbA1c, glycosylated hemoglobin; GI, gastrointestinal; eGFR, estimated glomerular filtration rate; DPP4, dipeptidyl peptidase 4; GLP-1, gluca-
gon-like peptide 1; GIP, gastric inhibitory polypeptide; CKD, chronic kidney disease; SGLT2, sodium-glucose cotransporter 2; DKA, diabetic 
ketoacidosis.
aMonotherapy.
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patients with T2DM who have a high risk of macrovascular 
events [45,46]. However, attention should be paid to increased 
edema, anemia, bone fracture, and heart failure risk in patients 
[46]. α-Glucosidase inhibitor is an effective agent for post-
prandial glucose control [47-49]; however, side effects such as 
gastrointestinal trouble are frequent, and there is a lack of evi-
dence for cardiovascular outcome [48,49]. Sulfonylurea and 
meglitinide have an excellent blood glucose-lowering effect. 
However, the cardiovascular benefit is not clear, and there is a 
risk of hypoglycemia [30,50]. Recent studies in Korea have 
shown that hypoglycemia is closely related to adverse out-
comes of patients [51-54]. Care should be taken with the use of 
drugs that are highly likely to cause hypoglycemia.
CONCLUSIONS
Diabetes treatment should be individualized according to the 
patient’s needs and preferences, and drugs should be selected 
taking into account the specific advantages and disadvantages 
of each drug [7]. For a reasonable choice of medication, vari-
ous clinical conditions should be considered including age, 
HbA1c, fasting and postprandial glucose, obesity or metabolic 
syndrome, insulin secretory capacity, risk of hypoglycemia, 
liver, cardiac or renal dysfunction, and patient preference.
Recently, new drugs have been introduced, and various clin-
ical trials related to these drugs have been introduced. Differ-
ent opinions on the selection of the initial treatment for pa-
tients with T2DM have been raised. We have yet to come to a 
complete conclusion as to which oral hypoglycemic agent 
should be the first choice for a particular patient, and which 
medication should be added next. In addition, we have not yet 
reached a consensus that it is reasonable to choose a particular 
medication for each of the various clinical situations. However, 
it is clinically more important to know what drug should con-
trol blood glucose, than what goal should blood glucose be 
controlled [17]. Even if blood glucose and HbA1c levels do not 
reach the target, the prognosis of the patient can be significant-
ly improved depending on the degree of improvement of these 
levels [1].
Based on the literature review so far, metformin can be rec-
ommended as the first drug in Korean patients with T2DM. 
Metformin can be recommended from the variety of evidence 
accumulated to date. If metformin is difficult to use as an ini-
tial treatment, appropriate alternatives should be chosen con-
sidering the patient’s individual circumstances. In addition to 
conventional drugs with which physicians have long-term ex-
perience such as sulfonylurea, thiazolidinedione, and α- 
glucosidase inhibitors, newer drugs such as the DPP4 inhibi-
tors and the SGLT2 inhibitors also are indicated for monother-
apy. If the goal of achieving glycemic control is not achieved by 
monotherapy, then combination therapy with different mecha-
nisms of action should be initiated promptly.
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